Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 282-299

  Carotti, Angelo ^a   Cadavid, Maria Isabel ^b   Centeno, Nuria B ^c   Esteve, Cristina ^d   Loza, Maria Isabel ^b   Martinez, Ana ^b   Nieto, Rosa ^b   Raviña, Enrique ^b   Sanz, Ferran ^c   Segarra, Victor ^d   Sotelo, Eddy ^b   Stefanachi, Angela ^a   Vidal, Bernat ^d  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d General Mitre 151 ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; HALOGEN; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; XANTHINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; RAT; REACTION ANALYSIS; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CHO CELLS; CRICETINAE; DRUG DESIGN; HELA CELLS; HUMANS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RECEPTOR, ADENOSINE A3; RECEPTORS, ADENOSINE A2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 30444448197     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0506221     Document Type: Article

References (60)

1. Cohn, L.; Elias, J. A.; Chupp, G. L. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 2004, 22, 789-815.
2. Frieri, M. Asthma concepts in the new millennium: update in asthma pathophysiology. Allergy Asthma Proc. 2005, 26, 83-8.
3. Szeleny, I.; Pahal, A. Drug Therapy in asthma bronchiale in the new millennium. Pharmazie 2002, 57, 83-86.
4. (a) Drazen, J. M.; Israel, E.; O'Byrne, P. M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999, 340, 197-206.
5. (b) Kemp, J. P. Recent advances in the management of asthma using leukotriene modifiers. Am. J. Respir. Med. 2003, 2, 139-156.
6. (c) Holgate, S. T.; Peters-Golden M. Introduction: the antiinflammatory role of cysteinyl leukotriene receptor antagonists in asthma. Allergy Clin. Immunol. 2003, 111, S1-4.
7. (a) Stokes, J.; Casale, T. B. Rationale for new treatments aimed at IgE immunomodulation. Ann. Allergy Asthma Immunol. 2004, 93, 212-217.
8. (b) Babu, K. S.; Holgate S. T. The role of anti-IgE therapies in the treatment of asthma. Hosp. Med. 2002, 63, 483-6.
9. Marx, D.; Ezeamuzie, C. I.; Nieber, K.; Szelenyi, I. Therapy of bronchial asthma with adenosine receptor agonists or antagonists. Drug News Perspect. 2001, 14, 89-100.
10. Holgate, S. T. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br. J. Pharmacol. 2005, 145, 1009-1015.
11. Jacobson, K. A.; IJzerman, Ad P.; Linden, J. 1,3-Dialkylxanthine derivatives having high potency as Antagonist at human A2B adenosine receptor. Drug. Dev. Res. 1999, 47, 45-53.
12. Klinger, M.; Freissmuth, M.; Nanoff, C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. 2002, 14, 99-108.
13. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 55, 527-552.
14. Baraldi, P. G.; Tabrizi, M. A.; Preti, D.; Bovero, A.; Romagnoli, R.; Fruttarolo, F.; Zaid, N. A.; Moorman, A. R.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P. A. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J. Med. Chem. 2004, 47, 1434-1447.
15. Volpini, R.; Costanzi, S.; Vittori, S.; Cristalli, G.; Klotz, K. N. Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem. 2003, 3, 427-443.
16. Cristalli, G.; Lambertucci, C.; Taffi, S.; Vittori, S.; Volpini, R. Medicinal chemistry of adenosine A2A receptor agonists. Curr. Top. Med. Chem. 2003, 3, 387-401.
17. Müller, C. E.; Stein, B.; Adenosine receptor antagonists: structure and potential therapeutic applications. Curr. Pharm. Des. 1996, 2, 501-530.
18. Baraldi, P. G.; Borea, P. A. New potent and selective human adenosine A3 receptor antagonists. Trends Pharmacol. Sci. 2000, 27, 456-459.
19. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Merighi, S.; Varani, K.; Borea, P. A.; Spalluto, G. A3 adenosine receptor ligands: history and perspectives. Med. Res. Rev. 2000, 20, 103-128.
20. van der Wenden, E. M.; IJzerman, A. P.; Soudijn, W. A. Steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor. J. Med. Chem. 1992, 55, 629-635.
21. Kim, Y. C; Ji, X.; Melman, N.; Linden, J.; Jacobson, K. A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J. Med. Chem. 2000, 43, 1165-1172.
22. 3 adenosine receptor antagonists. J. Med. Chem. 2002, 45, 770-780.
23. Soudijn, W.; van, Weden., I.; IJzerman, A. P. Medicinal chemistry of adenosine A1 receptor ligands. Curr. Top. Med. Chem. 2003, 3, 355-367.
24. Müller, C. E. Medicinal chemistry of adenosine A3 receptor ligands. Curr. Top. Med. Chem. 2003, 3, 445-462.
25. DeNinno, M. P.; Masamune, H.; Chenard, L. K.; DiRico, K. J.; Eller, C.; Etienne, J. B.; Tickner, J. E.; Kennedy, S. P.; Knight, D. R.; Kong, J.; Oleynek, J. J.; Tracey, W. R.; Hill, R. J. 3′-Aminoadenosine-5′- uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. J. Med. Chem. 2003, 46, 353-355.
26. Kim, Y. C.; Ji, X.; Melman, N.; Linden, J.; Jacobson, K. A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J. Med. Chem. 2000, 43, 1165-1172.
27. Hayallah, A. M.; Sandoval-Ramirez, J.; Reith, U.; Schobert, U.; Preiss, B.; Schumacher, B.; Daly, J. W.; Müller, C. E. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J. Med. Chem. 2002, 45, 1500-1510.
28. Kim, S. A.; Marshall, M. A.; Melman, N.; Kim, H. S.; Müller, C. E.; Linden, J.; Jacobson, K. A. Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J. Med. Chem. 2002, 45, 2131-2138.
29. Baraldi, P. G.; Tabrizi, M. A.; Preti, D.; Bovero, A.; Fruttarolo, F.; Romagnoli, R.; Moorman, A. R.; Gessi, S.; Merighi, S.; Varani, K.; Borea, P. A. [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorg. Med. Chem. Lett. 2004, 14, 3607-3610.
30. Hansel, T. T.; Tennant, R. C.; Tan, A. J.; Higgins, L. A.; Neighbour, H.; Erin, E. M.; Barnes, P. J. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. Drugs Today (Barc.) 2004, 40, 55-69.
31. Maconi, A.; Pastorin, G.; Da Ros, T.; Spalluto, G.; Gao, Z. G.; Jacobson, K. A.; Baraldi, P. G.; Cacciari, B.; Varani, K.; Moro, S.; Borea, P. A. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A3 adenosine receptor antagonist. J. Med. Chem. 2002, 45, 3579-3582.
32. Ongini, E.; Monopoli, A.; Cacciari, B.; Baraldi, P. G. Selective adenosine A2A receptor antagonists. Farmaco 2001, 56, 87-90.
33. Müller, C. E. A1 adenosine receptors and their ligands: overview and recent developments. Farmaco 2001, 56, 77-80.
34. Hayallah, A. M.; Sandoval-Ramirez, J.; Reith, U.; Schobert, U.; Preiss, B.; Schumacher, B.; Daly, J. W.; Müller, C. E. 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J. Med. Chem. 2002, 45, 1500-1510.
35. Baraldi, P. G.; Romagnoli, R.; Tabrizi, M. A.; Bovero, A.; Preti, D.; Fruttarolo, F.; Moorman, A. R.; Borea, P. A. New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. Farmaco 2005, 60, 185-202.
36. Grahner, B.; Winiwarter, S.; Lanzner, W.; Müller, C. E. Synthesis and structure-activity relationships of deazaxanthines: analogues of potent A1- and A2-adenosine receptor antagonists. J. Med. Chem. 1994, 37, 1526-1534.
37. Stefanachi, A.; Leonetti, F.; Cappa, A.; Carotti, A. Fast and highly efficient one-pot synthesis of 9-deazaxanthines. Tetrahedron Lett. 2003, 44, 2121-2123.
38. Carotti, A.; Stefanachi, A.; Raviña, E.; Sotelo, E.; Loza, M. I.; Cadavid, M. I.; Centeno, N. B.; Nicolotti O. 8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure-affinity relationships at A2B. Eur. J. Med. Chem. 2004, 39, 879-887.
39. Vidal, B. J.; Esteve Trias C.; Segarra Matamoros, V.; Ravina Rubira, E.; Fernandez Gonzales, F.; Loza Garcia, M. I.; Sanz Carreras, F. 6-Phenyldihydropyrrolo pyrimidinedione, 2003, WO 033694.
40. Senda, S.; Suzui, A.; Honda, M.; Fujimura, H. Uracil derivatives and related compounds. III. 5-Amino-1,3,6-trialkyluracil derivatives. Chem. Pharm. Bull. 1958, 6, 482-487.
41. Papesch, V.; Dodson, R. M. G. D. Pyrimido[5,4-d][1,2,3]triazines J. Org. Chem. 1963, 28, 1329.
42. Bicking, J. B.; Robb, C. M.; Watson, L. S.; Cragoe, E. J., Jr. (Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids. J. Med. Chem. 1976, 19, 544-547.
43. Agarwal, R.; Chaudray, C.; Singh, C. J.; Misra, V. S. Synthesis of 2-methoxy-4-(3-methyl-5-oxo-1-phenyl-4-pyrazolylidenemethyl)phenoxyacetic acid and its ethyl ester. Indian J. Med Chem Sect. B Org. Chem. Includ. Med Chem 1982, 21B, 152-153.
44. Albericio, F.; Barany, G. An acid-labile anchoring linkage for solid-phase synthesis of C-terminal peptide amides under mild conditions. Int. J. Pept. Protein Res. 1987, 30, 206-216.
45. Tipson, R. S. Antiviral Activity of 2,2-dichloro-4′- formylacetoanilide thiosemicarbazone. J. Med. Chem. 1963, 35, 216-217.
46. Cheng, M. F.; Fang, J. M. Liquid-phase combinatorial synthesis of 1,4-benzodiazepine-2,5-diones as the candidates of endothelin receptor antagonism. J. Comb. Chem. 2004, 6, 99-104
47. Behrens, G.; Hildenbrand, K.; Schulte-Frohlinde, D.; Herak, J. N. Reaction of sulfate radical anion with methylated uracils. An electron spin resonance study in aqueous solution. J. Chem. Soc., Perkin Trans. 2 1988, 3, 305-307.
48. Aichner, J.; Egg, H.; Gapp, D.; Haller, S.; Rakowitz, D.; Ramspacher, U. Insight into novel cyclization reactions using acetic anhydride in the presence of 4-dimethylaminopyridine. Heterocycles 1993, 36, 307-311.
49. Senda, S.; Suzui, A. Uracil derivatives and related compounds. I. Condensation of monosubstituted urea and ethyl acetoacetate. Chem. Pharm. Bull. 1958, 6, 476-479
50. Boese, A. B. 4-methyluracil and its homologs, US patent, 1938, 2,138,758.
51. Senda, S.; Hirota, K.; Banno, K. Pyrimidine derivatives and related compounds. 15. Synthesis and analgetic and antiinflammatory activities of 1,3-substituted 5-amino-6-methyluracil derivatives. J. Med. Chem. 1972, 15, 471-476.
52. Tipson, R. S. Antiviral Activity of 2,2-dichloro-4′- formylacetoanilide thiosemicarbazone. J. Med. Chem. 1963, 35, 216-217.
53. Tani, M.; Ikegami, H.; Tashiro, M.; Hiura, T.; TsuiKioka, H.; Kaneko, C.; Notoya, T.; Shimizu, M.; Uchida, M.; Regioselective Bromination of methoxy derivatives of ethyl indole-2-carboxylate [Synthetic studies of indoles and related compounds]. Heterocycles 1992, 34, 2349-2362.
54. Högberg, T.; Ström, P.; Ebner, M.; Rämsby, S. Cyanide as an efficient and mild catalyst in the aminolysis of esters. J. Org. Chem. 1987, 52, 2033-2036.
55. Jacobson, K. A.; Ukena, D.; Padgett, W.; Daly, J. W.; Kirk, K. L. Xanthine functionalized congeners as potent ligands at A2-adenosine receptors. J. Med. Chem. 1987, 30, 211-214.
56. Touchstone, J. Advances in Thin-Layer Chromatography, Wiley: New York, 1982.
57. Nieto, R. M.; Coelho, A.; Martinez, A.; Stefanachi, A.; Sotelo, E.; Ravina, E. Synthesis of 1-substituted-6-methyluracils. Chem. Pharm. Bull. 2003, 51, 1025-1028.
58. Salomon, Y. Adenylate cyclase assay. Adv. Cyclic Nucleotide. Res. 1979, 10, 35-55.
59. Prentice, D. J.; Hourani, S. M. O. Activation of multiple sites by adenosine analogues in the rat isolated aorta. Br. J. Pharmacol. 1996, 118, 1509-1517.
60. Alexander, S. P.; Losinsky, A.; Kendall, D. A.; Hill, S. J. A comparison of A2 adenosine receptor induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta. Br. J. Pharmacol. 1994, 111, 185-190.